OTC · Biotechnology

Ayala Pharmaceuticals, Inc. (ADXS) Stock

$0.60 +0.00% OTC: ADXS Healthcare

Ayala Pharmaceuticals, Inc., a clinical-stage oncology firm, focuses on developing and commercializing small molecule therapies for individuals battling rare tumors and aggressive cancers. Its primary drug candidates currently in development include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an innovative, proprietary anti-metabolite designed for first-line treatment in acute myeloid leukemia patients who are considered unfit.

Valuation

MetricValue
Price$0.60
Market Cap$25.71M
P/E Ratio-0.08
P/B Ratio-0.15
P/S Ratio1977.51
EPS (TTM)$-7.99
52-Week High$0.80
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE200.00%
ROA-289.96%
ROCE429.74%
Gross Margin0.00%
Operating Margin—
Net Margin—
Debt/Equity-0.34
Current Ratio0.30

Annual Financials (USD)

Metric20192020202120222023
Revenue$2.0M$0$3.0M$0$0
Operating Profit$-18.0M$-26.0M$-19.0M$-16.0M$-36.0M
Net Profit$-18.0M$-26.0M$-18.0M$-14.0M$-48.0M
EPS$-93.60$-34.71$-11.07$-7.90$-7.99
Op Margin-758.8%-10454.1%-579.8%-6436.0%-278969.2%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$20.0M$39.0M$47.0M$26.0M$17.0M
Total Liabilities$6.0M$8.0M$8.0M$2.0M$41.0M
Cash$17.0M$25.0M$42.0M$25.0M$5.0M
Borrowings$0$6.0M$0$0$8.0M

Latest News

Dow Jones Futures: Nvidia Lifts Dow, But Google, SpaceX Skid; Sandisk, Western Digital Lead Earnings Losers Late Investor's Business Daily · Aug 6, 2026 Herbalgy Trophy Ignites Hong Kong as Football Fever Sweeps the City PR Newswire · Aug 6, 2026 CORRECTING and REPLACING Aurelius Systems Secures $40M Series A to Meet Growing Demand for Counter-Drone Systems Business Wire · Aug 6, 2026 ICL (ICL) Q2 2026 Earnings Call Transcript Motley Fool · Aug 6, 2026 Back to the future as world champion Springboks host All Blacks AFP · Aug 6, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-15.0M$-22.0M$-15.0M$-15.0M$-29.0M
Investing Cash Flow$-3.0M$-1.0M$0$0$6.0M
Financing Cash Flow$-17.0M$0$4.0M$-5.0M$26.0M
Net Cash Flow$-9.0M$-7.0M$16.0M$-16.0M$2.0M
Free Cash Flow$-16.0M$-23.0M$-16.0M$-15.0M$-29.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.81
FCF Yield-114.69%
Quick Ratio0.30
Interest Coverage-2.30
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAGHAmerica Great Health $0.00 — 1.00 $2.12M 0.00%
AGNPFGrey Matters Health Inc. $0.25 -17.12% -0.43 $869804 0.00%
AGTXAgentix Corp. $0.02 +0.00% -2.00 $801339 0.00%
APLIFAppili Therapeutics Inc $0.01 +0.00% -0.44 $1.46M 0.00%
HESGHealth Sciences Group, Inc. $0.00 — 0.00 $1.87M 0.00%

About Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology firm, focuses on developing and commercializing small molecule therapies for individuals battling rare tumors and aggressive cancers. Its primary drug candidates currently in development include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an innovative, proprietary anti-metabolite designed for first-line treatment in acute myeloid leukemia patients who are considered unfit. The company is headquartered in Wilmington, Delaware.

Ayala Pharmaceuticals, Inc. is headquartered in US.

Ayala Pharmaceuticals, Inc. (ADXS) stock trades at $0.60 with a market capitalization of $25.71M. The stock is valued at a price-to-earnings (P/E) ratio of -0.08, price-to-book of -0.15, price-to-sales of 1977.51. Over the past 52 weeks the stock has ranged between $0.00 and $0.80, and currently trades 25.0% below its 52-week high.

On profitability, Ayala Pharmaceuticals, Inc. generates a return on equity (ROE) of 200.00% — well above the market average, a sign of a high-quality business, return on capital employed of 429.74%.

Official website: www.ayalapharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides